Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections

Intravitreal anti–vascular endothelial growth factor (anti-VEGF) agents have been increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen that these intravitreal agents may be associated with a potential risk of arterial thromboembolic (ATE) events. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Yun-I., Chang, Hao-Yun, Lin, Meng-Yin, Tseng, Ching-Han, Wang, Tsung-Jen, Lin, I-Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172364/
https://www.ncbi.nlm.nih.gov/pubmed/37165045
http://dx.doi.org/10.1038/s41598-023-34128-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172364/
https://www.ncbi.nlm.nih.gov/pubmed/37165045
http://dx.doi.org/10.1038/s41598-023-34128-5

Ejemplares similares